chrisvoncsefalvay/vaers-outcomes huggingface dataset:
No adverse affects reported; an inmproperly stored dose of PROQUAD was administered on 8/2/19; This spontaneous report was received from a nurse concerning a patient of unknown age and gender.  Information on pertinent medical history and drug reactions/allergies was not reported. Concomitant medications included sterile diluent.   On 02-AUG-2019, the patient was vaccinated with an improperly stored Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (strength, dose, dose number, route of administration and location of administration were not reported) (lot # R026351, expiration date 15-MAR-2020 and/or lot # S003171, expiration date: 30-JUL-2020); and on an unknown date, the patient was vaccinated with an improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (strength, dose, dose number, route of administration and location of administration were not reported) (lot # R010466, expiration date 10-APR-2020 and/or lot # R002056, expiration date: 22-JAN-2020). Both vaccines were administered for prophylaxis.   The vaccines were exposed to a temperature of -11.68 degree Celsius for 4 hours and 50 minutes as recorded by a digital data logger. There were no previous temperature excursions. No adverse effects were reported.
Caused me to test positive for COVID-19 10 days after receiving vaccine; Caused me to test positive for COVID-19 10 days after receiving vaccine; This is a spontaneous report from a contactable consumer (patient). A 54-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EP7534), via an unspecified route of administration in left arm on 17Mar2021 as single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. Patient caused to test positive for COVID-19 after receiving vaccine (drug ineffective).The patient underwent lab tests and procedures which included investigation: COVID-19 test positive on unspecified date .The outcome of the events was recovered with Sequel.
Patient  developed diffuse, erythematous  rash on legs, arms, torso, neck, face; very itchy rash that began 2 days after received the vaccine.   Tried  Benadryl and it helped a little, then rash changed and became bubble-like rash.  Finally resolved after 1 week.   Patient provided photos documenting a diffuse, significant erythematous macular rash.
nauseous; My son started feeling badly 5-6 hours after the 2nd shot./feeling overall very bad; this morning he had 103.5 fever; The patient was less  than 12 years old; This is a spontaneous report from a contactable consumer (parent). A 10-year-old male patient received bnt162b2 (COMIRNATY, solution for injection, Lot Number: not reported), via an unspecified route of administration, administered in Arm Left on 09Jun2021 00:30 (at the age of 10-years-old) as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient was allergic to Penicillin's and Sulfa. The patient previously received bnt162b2 (COMIRNATY, solution for injection, Lot Number: not reported), via an unspecified route of administration, administered in Arm Left on 19May2021, 12:00 (at the age of 10-years-old) as dose 1, single for COVID-19 immunisation. There were no other vaccine in four weeks and no other medications in two weeks. The patient was not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not having COVID prior vaccination and has not been COVID tested post vaccination. On 09Jun2021 00:30 The patient who was less than 12 years old took the vaccination and on 10Jun2021 07:30 the patient had 103.5 fever, nauseous and started feeling badly 5-6 hours after the 2nd shot feeling overall very bad. The patient started feeling badly 5-6 hours after the 2nd shot. At 7:30am morning he had 103.5 fever, nauseous and feeling overall very bad. Event treatment included Advil Tylenol swap every 4 hours so far. Laboratory data include fever 103.5. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Getting ready to go to recovery after vaccine. Leaned forward into me kept coming so I brought her slowly to the floor. Extremities rigid (approx. 3 seconds) then came to. Several nurses responded as well as EMT. Pt. placed on stretcher and cared for by EMT. Vitals taken. Family came to pick up after approximately 45 minutes.  Told EMT she has anxiety and has passed out before.
C/O "50 cent piece" size, raised, itchy rash just above belt line on his abdomen-started on Sun. 4/19/15. Also c/o backache at same time, but was doing manual labor over the weekend also. I referred him to his doctor for eval.
Headache, Myalgia, Arthralgia, Pain at site, fatigue Narrative:
After one hour of being vaccinated, loose bowel movements, and eyes and skin was sensitive, and had extreme vertigo for 2 weeks.
The morning after receiving the MENVEO vaccine (received at 4:30 pm) she awoke with a fever which increased throughout the day. Max temp was 102 orally. Was accompanied by chills,  generalized myalgia, and light headedness. Also mentioned neck stiffness and discomfort but was able to touch chin to chest. Fever and these associated symptoms continued for total of 2 days. On 3rd day after vaccination, symptoms gradually resolved and she became symptom free.
On 1/15/21, I had numbness and tingling, pain and burning in extremities.  Went to the ER, had MRI, had lumbar puncture, symptoms assessed, blood work and diagnosed with Guillian Barre.
History      Chief Complaint Patient presents with ? Elevated Blood Pressure ? Dizziness     multiple times a day   Patient who presents to the emergency department today for evaluation of hypertension, head pain, blurry vision, and neck pain. He states about 6 months ago he had open heart surgery. Since that time he states that he has been having intermittent episodes of blurry vision usually lasts a few minutes and resolve on their own. Today however, he notes that the blurry vision lasted for greater than 5 minutes and he started to become concerned. During that time he also began to experience some pain in his neck and a headache in the back of his head. He took his blood pressure at that time and noted that his systolic blood pressure was in the 190s. This alarmed him and so they called EMS. When EMS arrived they rechecked his blood pressure again and his systolic blood pressure was over 200. Upon arrival here to the ER he states that he is feeling much better and his blood pressure appears to be better as well. At this time he states he still having some right shoulder pain and a little bit of right-sided neck pain but he does state that he had his Covid vaccine yesterday in his right arm. Currently patient states he still has a little bit of a posterior headache but it is much improved. He denies any fevers, body aches, chills, cough, chest pain, shortness of breath, palpitations, lightheadedness, nausea, vomiting, abdominal pain, diarrhea, constipation, dysuria, hematuria, or swelling of the lower extremities. He has no known drug allergies.       ? ED Course: I discussed physical exam finding with patient. Apparently most of his symptoms have already resolved at this time. His blood pressure is back down to 142/98. I still advise since he was having some weird blurry vision I would like to get a CBC, CMP, troponin, EKG, and a chest x-ray. Patient agreeable to this plan of care. We will also continue to monitor his blood pressure to ensure that it does not spike back up.     Patient's work-up was unremarkable. His blood pressures down to 123/60 and states he is feeling much better. This point time it sounds like what happened was a hypertensive urgency. I advised him he needs to contact his PCP and schedule close follow-up discuss if anything further needs to be done. At this time though he is safe to be discharged home with strict return precautions.     ED Course Procedures Clinical Impressions as of Jan 20 2235 Hypertensive urgency     Plan:    New Prescriptions   No Prescriptions at Discharge.   Disposition: Discharge
28 weeks 6 days pregnant, Preterm rupture of the membrane. Admitted to the hospital at 29 weeks. Delivered at 29 weeks 4 days. Pregnancy was an IVF pregnancy with no other complications. Baby delivered on 3/16 and weighed 3 pounds 7 ounces.
pt has SLE & was having no sx when vax given 11SEP95; on 14SEP began to have pain & swelling in both wrists; 15SEP also started having pain in lt elbow & both hands; wrists are visibly mildly swollen
She stated that the morning after her shot, she woke up with her arm in severe pain and a lump where the pain was given. The lump has disappeared but she is still complaining of pain and weakness in the right arm.
I began breaking out with hives and bumps on my legs, arms, neck, scalp, and hands. It started three or four days after my second vaccine. The rash began on my legs and over the course of the next two and a half weeks, it spread to different areas. I finally went to an urgent care on April 15, 2021, to get a steroid shot because I was itching uncontrollably. They would not give me one and sent me to my regular doctor. She saw the rash and gave me a steroid shot, a prescription for steroids for seven days, and Hydrzyine for the itching.  I'm still having random bumps/breakouts here and there that consist of a couple of bumps at a time. I also felt as if there was a burning underneath my skin during this time. I'm currently rubbing Caladryl on the bumps when they itch. Most are gone,  but I did get two new ones a couple of days ago.
he got positive with Covid-19; dizziness; woke up sweating; chills; muscle spasms; can not eat; Coughing; This is a spontaneous case is received from a contactable consumer. A 60-years-old male patient received bnt162b2 (BNT162B2), via an unspecified route of administration on 29Mar2021 (Batch/Lot number was not reported) as single dose for COVID-19 immunisation. Medical history included from an unknown date and unknown if ongoing. Concomitant medication(s) included lisinopril (LISINOPRIL) taken for an unspecified indication, start and stop date were not reported; acetylsalicylic acid (ASPIRIN (E.C.)) taken for an unspecified indication, start and stop date were not reported; atorvastatin (ATORVASTATIN) taken for an unspecified indication, start and stop date were not reported. The patient experienced he got positive with covid-19 (sars-cov-2 test positive), dizziness on 06Apr2021, chills on 04Apr2021, muscle spasms on 04Apr2021, coughing (cough) on 01Apr2021, woke up sweating (hyperhidrosis) on 06Apr2021, cannot eat (feeding disorder)on 03Apr2021. The patient underwent lab tests and procedures which included sars-cov-1 test: positive. Therapeutic measures were taken as a result of, woke up sweating (hyperhidrosis). The outcome of the events sars-cov-2 test positive was unknown, chills, cough, feeding disorder were recovering, dizziness, hyperhidrosis were recovered on 06Apr2021, muscle spasms were recovered on 04Apr2021.  Follow-up activities have been completed and no further information is expected.
Chills; headache; exhaustion; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Aug2021 01:00 (Lot number: F(318) at the age of 52 years as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "Invasive breast cancer" (unspecified if ongoing). Concomitant medication(s) included: TAMOXIFEN; VENLAFAXINE; CALCIUM; VITAMIN D NOS. The following information was reported: CHILLS (non-serious) with onset 18Aug2021 07:00, outcome "not recovered", described as "Chills"; HEADACHE (non-serious) with onset 18Aug2021 07:00, outcome "not recovered", described as "headache"; FATIGUE (non-serious) with onset 18Aug2021 07:00, outcome "not recovered", described as "exhaustion". Therapeutic measures were not taken as a result of chills, headache, fatigue.  Additional information: Patient did not receive any other vaccine in four weeks. She received Tamoxifen, venlafaxine, calcium, vitamin D medications in two weeks. She did not have covid prior vaccination and did not test covid post vaccination. No Known allergies.  Follow-up attempts are completed. No further information is expected.
BUD 04/07/2022 VACCINATION given 04/08/2022 Pfizer advised product stable through 04/09/2022. Advised patient of situation and no further action required as use dat within range of 72 days.
Patient received Moderna vaccine first dose on 12/29/2020. Received Pfizer vaccine for second on 1/26/2021. Vaccine clinic not fully staffed on day when both vaccines were being administered in clinic for first time. No greeter present to direct patients to dedicated side of room for each vaccine which has separate workflows and dedicated vaccinators.
MODERNA COVID VACCINE #3 GIVEN 11/17/21, LOT #018F21A; 1/18/22 pt had a positive COVID test at facility where she lives; limited medical records; pt did not have any respiratory problems; pt passed away in the facility
Information was received from a licensed practical nurse concerning a 62 year old female patient. No information was received regarding past medical history, concurrent conditions or concomitant medications. On 19-MAY-2017 the adult patient was administered a pediatric dose of VAQTA lot # M036458, expiration date 02-MAR-2018 (dosage and route of administration unknown). No adverse effects reported. Additional information has been requested.
PATIENT COMPLAINED OF BLURRY VISION AND LIGHTHEADEDNESS.  DRANK WATER. COMPLAINED OF LEG WEAKNESS, SCRATCHY THROAT, DRY NASAL STUFFINESS.  BENADRYL 50MG PO GIVEN. PATIEN MONITORED. REPORTED SHE FELT BACK TO NORMAL.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 13 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 19Jun2021 15:30 (Lot number: EW0181) at the age of 13 years as dose 1, single for Covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DYSMENORRHOEA (non-serious) with onset 25Jun2021, outcome "recovered with sequelae" (2021), described as "Started to have very painful cramps when I menstruate"; NAUSEA (non-serious), MALAISE (non-serious) all with onset 25Jun2021, outcome "recovered with sequelae" (2021) and all described as "I get very nauseous and sick"; DECREASED APPETITE (non-serious) with onset 25Jun2021, outcome "recovered with sequelae" (2021), described as "No appetite". Therapeutic measures were taken as a result of dysmenorrhoea, nausea, malaise, decreased appetite. Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No any other medications the patient received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Patient reported her mother gave several Aleve for the pain. No follow-up attempts are possible. No further information is expected.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Pharmacist). The reporter is the patient.  A 57-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Sep2022 as dose 5 (booster), single (Lot number: Gh9694) at the age of 57 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Sleep apnea" (unspecified if ongoing); "Prostatic hypertrophy" (unspecified if ongoing); "Known allergies: Sulfa" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Ciprofloxacin, reaction(s): "Known allergies: Ciprofloxacin"; Diclofenac, reaction(s): "Known allergies: Diclofenac". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid from 06Dec2022 to 10Dec2022; Sender's Comments: Based on plausible dose -event relationship post vaccination and no other alternate explanation the causal role of BNT162B2 cannot be excluded for the reported LOE events,Linked Report(s) : US-PFIZER INC-202201378557 Same patient, different product and event;
No adverse event; Patient received first dose of vaccine after 30 days by used date in the refrigerator/ stored in refrigerator on 15-Sep-2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received first dose of vaccine after 30 days by used date in the refrigerator/ stored in refrigerator on 15-Sep-2022) and NO ADVERSE EVENT (No adverse event) in a 12-month-old male patient who received mRNA-1273 (Spikevax) (batch no. AR9236B) for COVID-19 prophylaxis.     No Medical History information was reported.   On 17-Oct-2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 17-Oct-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received first dose of vaccine after 30 days by used date in the refrigerator/ stored in refrigerator on 15-Sep-2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received first dose of vaccine after 30 days by used date in the refrigerator/ stored in refrigerator on 15-Sep-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patient received first dose of vaccine after 30 days by used date in the refrigerator/ stored in refrigerator on 15-Sep-2022).    Concomitant medications details were not reported by the reporter.  Vial size was reported as 2.5mL.  Reportedly, the dose was given after the 30 day by used date in the refrigerator after being thawed on 15-Sep-2022. No reported symptoms. No additional doses were reported. No temperature excursions were noted.  Treatment details and medication details were not reported by the reporter.
Person was given 0.3cc dose of Janssen Booster dose instead of standard 0.5 cc. Health Department notified and Manufacturer (Janssen) notified and all persons reported to Janssen Manufacturer for their Pharmacy department, recommendations from the Manufacturer and with agreement from health department are to notify all of the recipients that received an incorrect dose and submit a VAERS report for each.
Prevnar and Varivax given in left thigh 9/16/2003. 9/26 red, hot, swollen and hard. No fever. By 9/30 still red, not spreading, no longer hard, no fever to clinic and placed on Augmentin.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old male patient received BNT162b2 (BNT162B2), on 10Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 70 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and on 03Mar2022 as dose 4 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history was not reported. No known allergies were reported. There were no concomitant medications. No other medication was received within 2 weeks.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of drug ineffective, covid-19. Treatment included Paxlovid from 18May2022 to 22May2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Patient admitted to hospital 9/12/22 with c/o chest pain with non-STEMI and cough.
Approximately 12 hours after the vaccination, "extreme" arm pain and subsequent numbness occurred. She reports today that she has been to the emergency room twice in the subsequent days after the vaccination and is still having significant pain, numbness, and issues with her grip strength.
Pt received influenza vaccine- unsure of brand but office would have it.   14 days post influenza injection pt still has macular area of erythema. Has improved somewhat. Showed it to physician when we were there for Another illness (croup and fever, started 13 days after vaccine, seems unrelated)
pt c/o leg pain, limping, low grade fever x 2wk;pt tx Ibuprofen & observation @ home;
After about 12 minutes of receiving the vaccination patient started complaining of feeling dizzy.  He didn't feel normal
mom describes pt as having t102 p/vax given-went to sleep & woke up screaming w/h/a on same day immun; had n&v x 3 days; seen by MD states had a react to DTP vax;
Beginning on April 7 (Seven days after the second injection) at about 12:30 pm, I broke out in a bright red stinging rash all over my body.  The rash turned to solid red after approximately 10 minutes.  The event lasted about one hour.  The rash event occurs every day since at around the same time every day.  Each subsequent event is a little more diminished from the last.
Flu-like syndrome; sore throat, fever, chills, joint and muscle aches; local hard knot that was itchy and tender; discolored plaque formed over this; on 6/23, she developed multiple papules that turned urticarial; these occurred on face, arms, legs, buttocks, abdomen without angioedema or anaphylaxis.
Systemic: Dizziness/Lightheadedness-Severe, Systemic: Fainting/Unresponsive-Medium, Systemic: Flushed/Sweating-Medium, Additional Details: Patient had syncopal episode when walking away from vaccination area. Patient became conscious after 10 seconds of unresponsiveness. Patient hydrated and given food. Rested 30 minutes prior to leaving the pharmacy. After 6 hours, patient maintained that they are feeling well and not exhibiting any similar symptoms.
After receiving 1st dose covid vaccine patient became lightheaded and flushed. Patient has mild autism and communication is limited. Laid patient on cot. Vitals stable. Patient drank water and ate crackers and felt better. Patient discharged with Mother
Skin rash at the site of vaccination. (L) deltoid area more than 4"/6" - swelling, redness, induration with some pain around DTAP needle puncture site. Pt was afebrile.